Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User-Friendly OTC Dosage Forms Deliver Opportunity For Industry

Executive Summary

Hermes Pharma executive Thomas Hein recommends the OTC industry consider formulating APIs in user-friendly dosage forms, rather than in traditional tablets and capsules, to provide consumers with ease-of-swallowing and additional lifestyle convenience. Charts detail consumer preferences based on recent survey.

You may also be interested in...



Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs

While GSK Consumer Healthcare's latest ad campaign for Prevacid 24HR features "Lurker," a fireball character who educates consumers on the risk of recurrence of heartburn, oral disintegration of an active ingredient is the latest differentiator in the OTC PPI category.

Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs

While GSK Consumer Healthcare's latest ad campaign for Prevacid 24HR features "Lurker," a fireball character who educates consumers on the risk of recurrence of heartburn, oral disintegration of an active ingredient is the latest differentiator in the OTC PPI category.

What’s Next? Five Things To Look Out For In October

In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel